Compare TELA & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TELA | CELU |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 26.5M |
| IPO Year | 2019 | 2019 |
| Metric | TELA | CELU |
|---|---|---|
| Price | $0.69 | $0.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 122.1K | ★ 182.4K |
| Earning Date | 11-10-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.59 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $80,275,000.00 | $26,550,000.00 |
| Revenue This Year | N/A | $165.42 |
| Revenue Next Year | $8.83 | $305.36 |
| P/E Ratio | ★ N/A | $11.70 |
| Revenue Growth | ★ 15.84 | N/A |
| 52 Week Low | $0.50 | $0.46 |
| 52 Week High | $1.50 | $2.55 |
| Indicator | TELA | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 25.58 |
| Support Level | $0.60 | N/A |
| Resistance Level | $0.98 | $0.83 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 9.14 | 6.38 |
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.